> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ocugen's Quarterly Loss Shrinks To $3.6 Million On A Derivative Gain, Not Core Results
- URL: https://www.bullished.co/ocugens-quarterly-loss-shrinks-to-3-6-million-on-a-derivative-gain-not-core-results-5f65e76a/
- Published: 2026-11-04T13:36:11.000Z
- Updated: 2026-11-04T13:36:11.000Z
- Description: A $16.6 million non-cash gain cut the net loss from $20.1 million, while first Phase 3 data for OCU400 are expected in early 2027.
- Author: Matteo Parrino
- Tags: Earnings, OCGN, Industry: Healthcare

[Ocugen](https://www.bullished.co/tag/ocgn/), which develops gene therapies for blinding eye diseases, [cut its third-quarter net loss to $3.6 million](https://www.sec.gov/Archives/edgar/data/0001372299/000110465926122401/tm2628896d1%5Fex99-1.htm?ref=bullished.co) from $20.1 million a year earlier, but the improvement came from a $16.6 million non-cash gain on a derivative liability, according to results released Wednesday. The loss from operations was $17.8 million, in line with last year's $17.6 million.

## The gain behind the smaller loss

Operating expenses were $19.7 million, up from $19.4 million a year earlier. Research and development rose to $12.5 million from $11.1 million, while general and administrative costs fell to $7.2 million from $8.2 million.

Revenue from collaborative arrangements was $1.95 million, against $1.75 million in the year-earlier quarter. Interest expense was $3.1 million, up from $1.3 million.

Loss per share was $0.01, compared with $0.07 a year earlier, on 339.3 million shares outstanding at September 30\. For the first nine months, the net loss was $47.7 million, against $50.1 million a year earlier.

## Cash, notes and a deficit

Cash, cash equivalents, restricted cash and short-term investments totaled $84.6 million at September 30, which the company expects to fund operations into 2028\. At the end of 2025 the figure was $18.9 million.

The balance sheet also carries $83.1 million of convertible notes and a $17.1 million derivative liability. Stockholders' equity was a deficit of $17.7 million.

## Three late-stage programs and new licenses

Ocugen's lead candidate, OCU400 for retinitis pigmentosa, has enrolled 140 patients in its Phase 3 trial. Topline data are expected in the first quarter of 2027, followed by a planned Biologics License Application. CEO Shankar Musunuri said the company remains focused on "executing key clinical and regulatory milestones."

Ocugen signed a second regional OCU400 license, with Roots Pharmaceutical for the Middle East and North Africa, after Kwangdong Pharmaceutical in South Korea. It is eligible for up to $4 million in upfront and initial development payments, up to $255 million in sales milestones and a 22% royalty on net sales, and will make commercial supply.

In the Bahamas, OCU400 received provisional approval and priority designation, with final approval and patient enrollment possible as early as year-end. Dosing has begun in the 240-subject Phase 3 trial of OCU410 for geographic atrophy, an advanced form of dry age-related macular degeneration. Topline data for OCU410ST in Stargardt disease are expected in the second quarter of 2027.

The 140-patient OCU400 readout, expected in the first quarter of 2027, is the first of three Phase 3 results Ocugen is counting on.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Ocugen, Inc. (OCGN)](https://www.sec.gov/Archives/edgar/data/0001372299/000110465926122401/tm2628896d1%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2628896d1\_ex99-1.htm — Ocugen, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001372299/000110465926122401/tm2628896d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2628896d1\_ex99-2.htm — Ocugen, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001372299/000110465926122401/tm2628896d1%5Fex99-2.htm?ref=bullished.co) — SEC EDGAR

### More on Ocugen

- [Ocugen Says Bahamas Regulator Gave Provisional Approval To OCU400 Early Access Program](https://www.bullished.co/ocugen-says-bahamas-regulator-gave-provisional-approval-to-ocu400-early-access-program-60af3195/)
- [Ocugen Gives Roots Pharmaceutical Middle East Rights To OCU400 For Up To $255 Million In Sales Milestones](https://www.bullished.co/ocugen-gives-roots-pharmaceutical-middle-east-rights-to-ocu400-for-up-to-255-million-in-7cc2909e/)
- [Ocugen Pushes Vote On 250 Million More Authorized Shares To October 26](https://www.bullished.co/ocugen-pushes-vote-on-250-million-more-authorized-shares-to-october-26-7eb5850a/)

[All Ocugen (OCGN) coverage →](https://www.bullished.co/tag/ocgn/)